Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Therapeutic drug monitoring in inflammatory bowel disease
Konstantinos Papamichael, Adam S. Cheifetz
Current Opinion in Gastroenterology (2019) Vol. 35, Iss. 4, pp. 302-310
Open Access | Times Cited: 56

Showing 26-50 of 56 citing articles:

Therapeutic drug monitoring in inflammatory bowel disease patients on vedolizumab
Mohammed Ansari, Kerri Glassner, Malcolm Irani, et al.
Journal of Digestive Diseases (2024) Vol. 25, Iss. 2, pp. 91-99
Closed Access | Times Cited: 1
Subcutaneous infliximab cut-off points in patients with inflammatory bowel disease. Data from the ENEIDA registry
Marisa Iborra, Berta Caballol, Alejandro Garrido, et al.
Journal of Crohn s and Colitis (2024)
Closed Access | Times Cited: 1
Factors Influencing Drug Disposition of Monoclonal Antibodies in Inflammatory Bowel Disease: Implications for Personalized Medicine
Pavine Lefèvre, Lisa M. Shackelton, Niels Vande Casteele
BioDrugs (2019) Vol. 33, Iss. 5, pp. 453-468
Closed Access | Times Cited: 14
Association between ustekinumab trough concentrations and biochemical outcomes in patients with Crohn�s disease. A real life study
Rosa Gómez Espín, Isabel Nicolás de Prado, M Gil Candel, et al.
Revista Española de Enfermedades Digestivas (2020)
Open Access | Times Cited: 13
MRI-Based Radiomic Signature Identifying Secondary Loss of Response to Infliximab in Crohn's Disease
Jing Feng, Qi Feng, Yueying Chen, et al.
Frontiers in Nutrition (2022) Vol. 8
Open Access | Times Cited: 8
Identification of inadequate responders to advanced therapy among commercially-insured adult patients with Crohn’s disease and ulcerative colitis in the United States
Theresa Hunter, April N. Naegeli, Michael Grabner, et al.
BMC Gastroenterology (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 4
Strategies to improve the effect of mesenchymal stem cell therapy on inflammatory bowel disease
Meng-Yue Shi, Lian Liu, Fuyuan Yang
World Journal of Stem Cells (2022) Vol. 14, Iss. 9, pp. 684-699
Open Access | Times Cited: 7
Ustekinumab Therapeutic Drug Monitoring—Impact on Clinical Practice: A Multicenter Cross-Sectional Observational Trial
Waqqas Afif, Bernie D. Sattin, Dorota Dajnowiec, et al.
Digestive Diseases and Sciences (2021) Vol. 67, Iss. 7, pp. 3148-3157
Open Access | Times Cited: 9
Adalimumab Drug Levels at Secondary Loss of Response Do Not Predict Response to Dose-intensification in Crohn’s Disease: A Retrospective, International Multicenter Study
Robert D. Little, Adrian Swaine, Rebecca M. Reynolds, et al.
Inflammatory Bowel Diseases (2023) Vol. 30, Iss. 10, pp. 1714-1723
Closed Access | Times Cited: 3
The impact of proactive versus reactive drug monitoring of infliximab on treatment outcomes in patients with crohn’s disease
Yue Zhang, Wenyu Jiang, Chenjing Xu, et al.
Scandinavian Journal of Gastroenterology (2023) Vol. 59, Iss. 3, pp. 269-279
Closed Access | Times Cited: 3
Therapeutic Drug Monitoring of Biologics in IBD: Essentials for the Surgical Patient
Rodrigo Bremer Nones, Phillip Fleshner, Natália Sousa Freitas Queiroz, et al.
Journal of Clinical Medicine (2021) Vol. 10, Iss. 23, pp. 5642-5642
Open Access | Times Cited: 7
Practical Aspects of Proactive TDM for Anti-TNF Agents in IBD: Defining Time Points and Thresholds to Target
Camilla de Almeida Martins, Alan C. Moss, Carlos Walter Sobrado, et al.
Crohn s & Colitis 360 (2019) Vol. 1, Iss. 3
Open Access | Times Cited: 7
Is It Prime Time for Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease?
Konstantinos Papamichael, Adam S. Cheifetz
Gastroenterology (2019) Vol. 157, Iss. 4, pp. 922-924
Open Access | Times Cited: 6
Fast clearance of anti-TNFα agents unrelated to antidrug antibodies: a case report
Stefania Cheli, Valeria Cozzi, Dario Cattaneo, et al.
European Journal of Clinical Pharmacology (2022) Vol. 78, Iss. 5, pp. 891-893
Closed Access | Times Cited: 3
Ustekinumab Drug Levels and Outcomes in Inflammatory Bowel Disease
Jessica C. Petrov, Sean Fine, Raneem Alzahrani, et al.
Journal of Clinical Gastroenterology (2024) Vol. 59, Iss. 1, pp. 77-81
Closed Access
Practical guidance for managing patients with moderate-to-severe ulcerative colitis using small molecule therapies
Vipul Jairath, Waqqas Afif, Brian Bressler, et al.
Journal of the Canadian Association of Gastroenterology (2024) Vol. 7, Iss. 4, pp. 282-289
Open Access
Therapeutic drug monitoring in inflammatory bowel diseases. Position statement of the Spanish Working Group on Crohn’s Disease and Ulcerative Colitis
Francisco Rodríguez‐Moranta, Federico Argüelles‐Arias, Joaquín Hinojosa del Val, et al.
Gastroenterología y Hepatología (English Edition) (2024) Vol. 47, Iss. 5, pp. 522-552
Open Access
Use of upadacitinib in a child with refractory ulcerative colitis
А. С. Потапов, A. E. Pushkareva, A.V. Vinokurova, et al.
Meditsinskiy sovet = Medical Council (2024), Iss. 13, pp. 124-129
Open Access
Treatment patterns for advanced therapies in Canadians with moderate-to-severe inflammatory bowel disease: a retrospective cohort analysis
Laura E. Targownik, Waqqas Afif, Sunny Singh, et al.
Journal of the Canadian Association of Gastroenterology (2024) Vol. 8, Iss. 1, pp. 21-30
Open Access
One Concentration Does Not Fit All: It is Time to Personalize the Therapeutic Range of Infliximab in Crohn Disease
Bénédicte Franck, Camille Tron, Marie‐Clémence Verdier, et al.
Therapeutic Drug Monitoring (2024)
Closed Access
Safety, Efficacy and Persistence of Advanced Therapies in Inflammatory Bowel Disease: Results from ORIGINS. A Retrospective Observational Study
Bogdan Mateescu, Cristian Gheorghe, Anca Trifan, et al.
Journal of Gastrointestinal and Liver Diseases (2023) Vol. 32, Iss. 4, pp. 444-451
Open Access | Times Cited: 1
The impact of pregnancy on biologic therapies for the treatment of inflammatory bowel disease
Sherman Picardo, Cynthia H. Seow
Best Practice & Research Clinical Gastroenterology (2020) Vol. 44-45, pp. 101670-101670
Closed Access | Times Cited: 3
Therapeutic Drug Monitoring
Robert J. Flanagan, Eva Cuypers, Hans H. Maurer, et al.
(2020), pp. 479-504
Closed Access | Times Cited: 3
Therapeutic drug monitoring in inflammatory bowel disease: At the right time in the right place
Brindusa Truta
World Journal of Gastroenterology (2022) Vol. 28, Iss. 13, pp. 1380-1383
Open Access | Times Cited: 2
Treating inflammatory bowel diseases in the 21<sup>st</sup> century: individualized therapy and telemedicine
Milan Lukáš
Vnitřní lékařství (2021) Vol. 67, Iss. 4, pp. 201-205
Open Access | Times Cited: 2

Scroll to top